Innovating antibodies, improving lives

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

 

financial news 260x1732018 Full Year Financial Results

Genmab will report its 2018 Full Year financial results after market close on February 20. An investor conference call to discuss the results will be held at 6:00 PM CET / 12:00 PM EST on February 20. To join the call by phone, dial one of the following numbers and provide confirmation code 8793105: +45 32728042 in Denmark, +44 (0) 2071 928000 in the UK or +1 8669661396 in the US. Click here to listen to the webcast. 

 

Investorportal sign on_260x173InvestorPortal

To register your email address for electronic shareholder communications or to update your settings, log on to the InvestorPortal.  

 

 

Join our teamCareer Opportunities at Genmab

Genmab is seeking new employees to join our team. Visit our Careers webpages to explore current vacancies, learn about our culture and meet some of our team members. Click here to visit Genmab's page on LinkedIn.